Zachariah DeFilipp

CONGRESS | #EBMT26 | PRESENTATION Zachariah DeFilipp discusses results from a comprehensive, integrated analysis of two clinical trials, evaluating axatilimab in patients with #cGvHD and related BOS (N = 117). The NIH lung response rate on study was 38.5%, with a median time to first response of 2.6 months. Response rates were consistent across baseline lung involvement, including 37.1% vs 40.5% in patients with baseline FEV1 >39% vs ≤39%, respectively, and 37.0% vs 40.2% in patients with NIH lung scores of 3 vs <3, respectively. Among 75 evaluable patients, 32.0% had ≥5% absolute improvement and 20% had a ≥10% absolute improvement in FEV1% from baseline. Follow our live feed for more updates: bit.ly/4lyVG9v Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #GvHD #GvHDsm #MedNews #MedEd @TheEBMT @DrZackDeFilipp @MassGeneralNews

CONGRESS | #Tandem26 | POSTER Zachariah DeFilipp shares findings from an analysis of two prospective clinical trials and a long-term follow-up study evaluating belumosudil in patients with sclerotic skin and fascial #cGvHD (N = 159). Belumosudil achieved clinical responses across skin and joints/fascia, with ORRs of 28.3% in skin and 62.3% in joints/fascia. Median TTR was 12.0 weeks in the overall cohort. Multivariable analysis showed that higher baseline Lee skin symptom burden was associated with higher risk of treatment discontinuation (HR, 1.89, p = 0.0167), while higher baseline Lee skin and joint composite symptom burden was associated with lower QoL (p = 0.0003). Clinical severity rating correlated with corticosteroid dose reduction (p = 0.0006). Follow our live feed for more updates: loom.ly/w1Z1fZ8 Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. @DrZackDeFilipp @MassGenBrigham @harvardmed #GvHD #GvHDsm #MedEd #MedicalCongress

CONGRESS | #Tandem26 | PRESENTATION Zachariah DeFilipp presents results of an integrated analysis describing clinical outcomes of axatilimab in patients with cGvHD-BOS at baseline from two clinical trials (a phase I/II trial and the AGAVE-201 trial; N = 117). The NIH lung response rate was 38.5%, with a median time to first lung response of 2.6 months. NIH lung responses were 37.1% and 40.5%, for patients with baseline FEV1 >39% and ≤39%, respectively; and 37.0% and 40.2% for patients with baseline NIH lung symptom scores of 3 and <3, respectively. The safety profile of axatilimab in this subanalysis was similar to that of the full study populations. Follow our live feed for more updates: loom.ly/w1Z1fZ8 Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. a full list of supporters can be found on our website. #GvHD #GvHDsm #MedEd #MedicalCongress @DrZackDeFilipp, Mass General Brigham Cancer Institute

Huge thanks to @DrZackDeFilipp, @hamiltkyb and Amandeep Salhotra, MD for an insightful #ASH25 #GVHD session! Practical insights clinicians can use in real-world patient care. 📺 Watch the replay: bit.ly/2025-GVHD-T Grateful to @Incyte, @Mesoblast, @OrcaBio, and @Sanofi for grant support, and to @BMTInfoNet for partnering with us! #CME #MedEd

Stay current with the latest data on approved and emerging therapies for the treatment of acute and chronic GVHD with @DrZackDeFilipp, @hamiltkyb, & Dr. Amandeep Salhotra. 12/5 at 7 AM EST. Produced with @BMTInfoNet. #ASH25 #Hematology

👉⭐️Truly thrilled to see this in press- Rux-before, during, after-HCT for MF = very low GVHD and excellent PFS/OS. Thank you to all the sites, PIs, Incyte for supporting this and most of all our patients! JCO OA 😀ascopubs.org/doi/10.1200/OA… #MPNSM #MGH

CONGRESS | #Tandem25 | PRESENTATION Yi-Bin Chen, @harvardmed, provides insights into the role of MRD testing in post-HCT maintenance for AML. He discusses various maintenance treatment options, including FLT3 inhibitors, HMAs, IDH1/2 inhibitors, and menin inhibitors, and their importance in preventing post-HCT relapse. He also highlights the need for uniform, highly sensitive MRD assays, such as mutation and host-specific assays, as well as individualized blood-based MRD assays that could help identify patients for maintenance therapy, guide pre-emptive strategies, determine optimal treatment duration, and guide the use of cellular therapy. Follow our live feed for more updates: aml-hub.com/medical-inform… #leusm #AMLsm #MedicalCongress

Ruxolitinib therapy was associated with improvements in lung function for participants with BOS. ow.ly/5Tqp50UPn6I #clinicaltrialsandobservations #transplantation

Gain insight on cutting-edge clinical evidence supporting targeted, immune & cell-based strategies for the prevention & treatment of #GVHD with Drs Zachariah DeFilipp (@DrZackDeFilipp), & Betty K. Hamilton (@hamiltkyb), on 2/14 at 6:30 AM HST. bit.ly/PVITandem2T #Tandem25

Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy If no matched donor then upfront Haplo BMT an option now #PTCyRules #ASH24 astctjournal.org/article/S2666-…

CONGRESS | #cGvHD2024 @DrZackDeFilipp spoke about the treatment of cGvHD from the 2020 NIH consensus. Larger trials lack correlative analyses, and there is a need for innovative trial design. Steroid-free monotherapies in the first line are lacking but should remain a long-term goal. #GvHD

A study in patients with chronic GVHD evaluated three doses of axatilimab, a colony-stimulating factor 1 receptor antibody. The lowest dose appeared to maximize response with the fewest adverse effects. Full AGAVE-201 trial results: nej.md/3Zpi8sw

Initial treatment with third-party FMT and corticosteroids is associated with high response rates in LGI acute GVHD. ow.ly/5Ay050RG6Lw #transplantation

@DrZackDeFilipp , 3rd party FMT for high risk LGI GVHD n=10, 9/10 completed all doses, 70% response rate at D28, increase in alpha diversity after FMT, expansion of donor derived species in recipients post FMT. doi.org/10.1182/blooda…

New therapeutics are showing promise for #GVHD treatment! Hear the latest data in our new CME/MOC activity, presented by @DrZackDeFilipp bit.ly/3tw0cyP

#ICYMI: Watch our free #CME program on-demand to review the efficacy of existing and emerging therapies for chronic Graft-versus-Host Disease (#GvHD) ➡️ bit.ly/4aExJH6 Discussion led by @DrZackDeFilipp, MD and Andrew Rogers, MD, MS #MedEd #MedicalEducation

@ASTCT @MassGeneralNews @xnyerin @MoffittNews Thank you @ASTCT for your support, going back to when I was a trainee. I look forward to continued opportunities to give back!

Congratulations to 2024 ASTCT Envoys @DrZackDeFilipp of @MassGeneralNews and Rebecca Gonzalez (@xnyerin), PharmD, BCOP of @MoffittNews. #Tandem24

Coming soon! Join @DrZackDeFilipp and Dr. Andrew Rogers to review new data on existing and emerging therapeutic approaches for chronic #GvHD and their application in academic and community settings ➡️ bit.ly/3wedxgo #FreeCME #MedEd #CME

Despite new therapeutic agents and ongoing research in #GvHD, significant disease burden is common. Join @DrZackDeFilipp during our free #CME program with @RareDiseases to discuss effective strategies for improving patient #QoL ➡️ bit.ly/3tE20Gf #RareDiseases #MedEd

CONGRESS #ASH23 | @DrZackDeFilipp @MGHCancerCenter shares data from a phase II trial of ruxolitinib for the treatment of BOS following allo-HCT. Results show meaningful clinical responses in BOS across all severity levels, with low levels of severe AEs, supporting the use of ruxolitinib in the management of BOS. #GvHDsm #medicalcongress #GvHD